iJRASET
International Journal For Research in Applied Science and Engineering Technology

INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY

Volume: 13 **Issue:** IV **Month of publication:** April 2025

DOI: https://doi.org/10.22214/ijraset.2025.68392

www.ijraset.com

Call: 08813907089 | E-mail ID: ijraset@gmail.com

International Journal for Research in Applied Science & Engineering Technology (IJRASET)
ISSN: 2321-9653; IC Value: 45.98; SJ Impact Factor: 7.538
Volume 13 Issue IV Apr 2025- Available at www.ijraset.com

Identifying Side Effects of Adverse Drug Reactions via Drug-Drug Interactions with Advanced Neural Network Techniques

Karra Maheswari[1], G. Indiravathi[2], Mabbu Mythri[3], Bantupalli Lazar[4], J G Rajesh[5], Utukuri Reddy Kalyan[6]
[1, 2]*Assistant Professor* , [3, 4, 5, 6]*UG Student, Department of Computer Science and Engineering Siddharth Institue of Engineering Technology Tirupathi, Andhra Pradesh, India*

Abstract: ***Adverse Drug Reactions (ADRs) due to drug-drug interactions pose a significant public health issue, impacting mortality, morbidity, and healthcare costs. The increasing complexity of therapeutics and aging populations intensify these challenges. Currently, no standard method exists to detect such ADRs before drugs reach the market, as rare interactions often emerge only after patient reports. Clinical trials struggle to capture these rare effects. Thus, a reliable technique to predict ADRs prior to drug release is urgently needed. We propose an effective framework that models drug-drug interactions using Graph Neural Networks (GNNs) and self-supervised learning. By representing drugs as molecular graphs, our approach leverages their spatial and physical properties to enhance predictive capabilities, offering a promising solution to mitigate ADR risks early in the drug development process.***

Keywords: Self-Supervised Learning (SSL) techniques, drug-drug interactions (DDIs)

I. INTRODUCTION

Adverse drug reactions (ADRs) are a significant cause of morbidity and mortality worldwide, posing a serious challenge to public health and clinical practice. Despite extensive research into drug safety, the detection and prediction of ADRs remain complex due to the multifactorial nature of drug interactions and their diverse effects on the human body. Interaction is the process by which two or more things act upon or influence each other. A substantial number of ADRs arise from interactions between different drugs, leading to unexpected side effects that can range from mild discomfort to life-threatening conditions. Understanding these drug-drug interactions (DDIs) and their role in triggering ADRs is essential for enhancing the safety and efficacy of pharmaceutical treatments[1].

Traditionally, ADR detection has relied on clinical trials, post-market surveillance, and expert pharmacovigilance. While these methods provide valuable insights, they have limitations in terms of cost, time, and the ability to detect rare or unforeseen interactions[2]. Furthermore, the sheer volume of drugs on the market and the complexity of their interactions make it difficult to manually analyze all potential drug combinations. This underscores the need for automated, data-driven approaches capable of efficiently predicting ADRs from large-scale drug interaction data.

In recent years, machine learning (ML) and deep learning (DL) techniques have emerged as powerful tools for analyzing complex relationships in large biomedical datasets. Graph-based methods, particularly Graph Neural Networks (GNNs), have shown great promise in modeling and predicting DDIs due to their ability to capture the intricate dependencies between drugs and their interactions. GNNs represent drugs and their interactions as graphs, where drugs are nodes and interactions are edges, making them ideal for analyzing drug-related data in a structured and dynamic manner[3].

Additionally, Self-Supervised Learning (SSL) techniques have gained attention for their ability to learn useful features from unlabeled data by creating auxiliary tasks that help the model develop meaningful representations. This is particularly valuable in drug interaction prediction, where labeled datasets may be scarce, but vast amounts of unlabeled drug interaction data are available. By integrating GNNs with SSL, we can harness the power of both techniques to predict ADR-related side effects more accurately, even in the absence of extensive labeled datasets[4].

This paper presents a novel approach to detecting ADRs by leveraging Graph Neural Networks combined with Self-Supervised Learning to model drug-drug interactions. We aim to provide a more efficient, scalable, and reliable method for predicting ADRs, offering new insights into drug safety that can help guide clinical decision-making and inform drug development.

II. LITERATURESURVEY

In [5], recent years, machine learning (ML) techniques have gained significant attention due to their ability to model complex, non-linear relationships and learn from large-scale data without explicit programming. Several studies have explored ML algorithms for ADR prediction, including decision trees, support vector machines (SVM), and random forests. Kuhn et al. (2016) demonstrated the use of decision trees in predicting drug toxicity and ADRs, but these methods often struggle with high-dimensional and unstructured data.

In [6], Zhang et al. (2020) proposed a GNN-based model for predicting drug interactions, where they represented the drug interaction network as a graph and used GNNs to predict ADRs based on the interactions between drugs. Their results showed that GNNs can outperform traditional machine learning methods in predicting drug-related side effects..

In [7], Cao et al. (2018) used graph convolutional networks (GCNs) to predict potential DDIs and their associated ADRs. The model used graph representations of drugs and interactions and successfully identified previously unrecognized DDIs. These graph-based models, however, require large amounts of labeled data to perform effectively, which can be a significant limitation in domains where labeled data is scarce.

In [8], Zhou et al. (2018) proposed a hybrid deep learning model that combined convolutional neural networks (CNNs) and GNNs for predicting ADRs. This hybrid approach effectively utilized both structured data (drug interaction networks) and unstructured data (drug properties). Similarly, Xie et al. (2021) explored the combination of GNNs with reinforcement learning to predict DDIs and ADRs, achieving state-of-the-art performance on various drug safety prediction tasks.

In [9], For instance, Zhou et al. (2018) proposed a hybrid deep learning model that combined convolutional neural networks (CNNs) and GNNs for predicting ADRs. This hybrid approach effectively utilized both structured data (drug interaction networks) and unstructured data (drug properties). Similarly, Xie et al. (2021) explored the combination of GNNs with reinforcement learning to predict DDIs and ADRs, achieving state-of-the-art performance on various drug safety prediction tasks.

III. PROPOSED SYSTEM

The proposed system aims to predict and detect Adverse Drug Reactions (ADRs) caused by Drug-Drug Interactions (DDIs) by utilizing Graph Neural Networks (GNNs) in conjunction with Self-Supervised Learning (SSL) techniques. The system is designed to represent drug interactions as a graph, where each drug is a node, and interactions between drugs are edges. This approach allows the model to capture the complex relationships and dependencies between drugs, facilitating a more accurate prediction of potential ADRs.

In the proposed model, drugs are represented as nodes, with attributes such as chemical properties, molecular structures, and drug classifications. The edges in the graph represent interactions between drugs, with each edge containing information about the type and strength of the interaction. This graph structure is ideal for representing the dynamic and multifaceted nature of drug-drug interactions, providing the model with a robust framework for learning complex patterns associated with ADRs.

To process this graph-based data, the system employs Graph Neural Networks (GNNs). GNNs are particularly suited for this task as they excel at learning from structured data, capturing the intricate dependencies between drugs and their interactions. By aggregating information from neighboring nodes, the GNN can propagate drug-related information throughout the graph and learn how the properties of drugs influence the likelihood of ADRs when combined with other drugs. Through this process, the model is trained to predict ADRs based on the drug interaction graph, making it highly effective at identifying potential side effects caused by specific drug combinations.

In addition to GNNs, the proposed system incorporates Self-Supervised Learning (SSL) techniques to address the challenge of limited labeled data, which is common in ADR prediction. SSL enables the model to learn meaningful representations from large amounts of unlabeled data by creating surrogate tasks that help the model develop generalized features. This is particularly useful in the domain of drug prediction, where labeled data is often scarce. SSL is used to pre-train the GNN on a large drug interaction graph before fine-tuning the model with available labeled data. This pre-training process helps the system to extract valuable patterns and features from the graph, improving its ability to predict ADRs when trained on smaller labeled datasets.

The system undergoes two phases of training. The first phase involves pre-training the GNN using SSL on the unlabeled drug interaction graph. During this phase, the model learns the relationships between drugs and their interactions. The second phase is fine-tuning, where the model is trained on a labeled dataset containing information about known ADRs. In this phase, the model refines its predictions by learning to associate specific drug combinations with the occurrence of ADRs. The system is evaluated using a range of metrics, including accuracy, precision, recall, F1-score, and AUC-ROC, to assess its performance in predicting ADRs.

Once trained, the system can predict the likelihood of ADRs for new or unseen drug combinations. For each drug pair, the model generates a prediction score that indicates the potential for an adverse reaction. This prediction can be used to inform healthcare providers, helping them identify high-risk drug combinations and make better clinical decisions. The system ranks drug combinations based on their predicted ADR risk, enabling clinicians to prioritize further investigation or additional testing for certain drug pairs.

The proposed system provides multiple benefits compared to conventional approaches. It significantly improves prediction accuracy by utilizing GNNs, which can capture complex relationships between drugs that are often overlooked by simpler models. The incorporation of SSL addresses the issue of limited labeled data, enabling the model to learn effectively from large amounts of unlabeled drug interaction data. Additionally, the system is scalable, capable of processing large interaction networks and identifying potential ADRs for a wide variety of drug combinations. By predicting ADRs early, the system helps mitigate the risks associated with drug-drug interactions, ultimately improving patient safety and clinical outcomes.



Fig 1. Proposed System Architecture

1) Atom Feature Extraction

This step extracts molecular-level features of drugs.Atoms in drug molecules are represented with their chemical properties such as atomic number, valency, hybridization, and electronegativity.The diagram shows molecular structures and how atom-level features are extracted for further processing..

The chemical structures of Warfarin and Aspirin are analyzed at the atomic level.Features like atomic number, valency, electronegativity, and hybridization are extracted.

2) Bond Feature Extraction

Bonds between atoms in drug molecules are analyzed.Features such as bond type (single, double, triple, or aromatic), conjugation, and ring membership are considered.This information is crucial for understanding the interaction between different drug molecules.

The types of bonds in Warfarin and Aspirin are identified, such as single, double, and aromatic bonds.

Bond attributes (conjugation, ring structures) are extracted.

.

3) Graph Latent Space Embeddings

Atoms and bonds are represented as a graph where atoms are nodes and bonds are edges.Graph neural networks (GNNs) process these graphs to generate latent (hidden) representations that capture molecular properties.These embeddings serve as meaningful representations of drug molecules in a high-dimensional space.

Formula:

The formules for extraing to calculating the
Drug interaction Using KNN of Self Supervised
Learing

- Euclidean Distance (Most common) d(A,B)=∑(xi−yi)2d(A, B) = \sqrt{\sum (x_i - y_i)^2}d(A,B)=∑(xi−yi)2
- ManhattanDistance d(A,B)=∑|xi−yi|d(A, B) = \sum |x_i - y_i|d(A,B)=∑|xi−yi|
- Minkowski Distance (Generalized form of Euclidean&Manhattan) d(A,B)=(∑|xi−yi|p)1/pd(A, B) = \left(\sum |x_i - y_i|^p \right)^{1/p}d(A,B)=(∑|xi−yi|p)1/p.

4) Dual Path Graph Classifier

This component takes the graph embeddings of two drugs and evaluates their interaction.It consists of two paths: one for processing individual drug graphs and another for analyzing interactions.A classifier is trained to predict whether the interaction leads to an adverse drug reaction.

The embeddings of Warfarin and Aspirin are processed in two paths:

- Individual drug graph embeddings (to capture their molecular properties).
- Interaction graph embeddings (to understand how these drugs affect each other)

5) Probability Projection

The model outputs the probability of specific adverse effects occurring due to drug interactions.Higher probabilities indicate a greater risk of certain side effects.

6) Predicted Adverse Side Effects

The final output is a list of potential adverse reactions, such as:

- Leukocytosis
- Hypermagnesemia
- Lung Edema
- Thrombocytopenia

IV. RESULT AND DISCUSSION

1) Experimental setup:



ISSN: 2321-9653; IC Value: 45.98; SJ Impact Factor: 7.538
Volume 13 Issue IV Apr 2025- Available at www.ijraset.com

The system requirements for this project include both hardware and software specifications. The hardware requirements are modest, featuring an Intel® Core™ i3-4200U processor with a clock speed of 1.6 GHz, which ensures smooth operation for most tasks. The system needs 4 GB of RAM, providing enough memory for handling moderate workloads and multitasking. For storage, a 500 GB hard disk is required, offering ample space for data and applications.On the software side, the project is designed to run on the Windows 10 operating system, which is a widely used and stable platform. To facilitate the development and deployment of the project, the XAMPP Server is used, enabling the use of Apache, MySQL, and PHP for local server management. The frontend of the project is built using HTML, CSS, and JavaScript, which are standard technologies for creating interactive and responsive web pages. For the backend, Python is chosen due to its versatility and ease of use in handling server-side logic. The MySQL database will be used for storing and managing data, offering reliability and scalability. Finally, the project will be developed using the PyCharm IDE, which provides powerful tools for Python development, ensuring a smooth and efficient coding experience.

Result:

The proposed system was evaluated using real world datasets that contain drug interaction information and known ADR reports. The dataset includes various drug pairs, their interactions, and associated side effects. The model was tested using different evaluation metrics such as accuracy, precision, recall, F1-score, and AUC-ROC to assess its ability to predict ADRs based on drug drug interactions.



The bar graph compares the performance of two convolution techniques (Graph Convolution and Spectral Convolution) using two different weight initialization strategies:

- Red bars represent Random Weights
- Purple bars represent Pretrained Weights

Detailed Observations

Graph Convolution

- Random Weights (Red): Approximately 40 units
- Pretrained Weights (Purple): Around 75 units
- Performance Improvement: Approximately 67% increase with pretrained weights

Key Insights

- ➢ Pretrained weights consistently outperform random weights for both convolution methods
- ➢ Spectral Convolution shows slightly higher overall performance
- ➢ The use of pretrained weights significantly enhances model performance

Potential Implications

- Demonstrates the value of transfer learning
- Suggests that pretraining captures important feature representations
- Indicates the effectiveness of knowledge transfer in neural network architectures

The system demonstrated impressive performance, particularly in comparison to traditional machine learning models. The Graph Neural Network (GNN) architecture allowed the model to capture complex relationships between drugs and their interactions, leading to highly accurate predictions of potential ADRs. The combination of Self Supervised Learning (SSL) significantly improved the model's ability to generalize from the limited labeled data, which is often a challenge in ADR prediction tasks.

Pre-training on a large, unlabeled drug interaction graph helped the model learn useful features, even in the absence of extensive annotations. When compared to baseline models, such as traditional support vector machines (SVM) and random forests, the proposed system showed a marked improvement in terms of recall and precision, indicating that it was better at both identifying potential ADRs and minimizing false positives. The AUC-ROC curve also confirmed that the model's overall discriminatory power was superior, making it more reliable for clinical decision-making.



The graph illustrates the fascinating journey of a machine learning model's loss reduction during training, revealing the intricate process of knowledge acquisition and model refinement. At first glance, the visualization captures the dramatic transformation of the model's performance across multiple training epochs.

The most striking feature is the steep initial descent of the loss values, particularly evident in the blue curve. This rapid decline represents the model's most aggressive learning phase, where it quickly captures the fundamental patterns and relationships within the training data. During the first 10 to 20 epochs, the model undergoes its most significant transformation, rapidly reducing error and improving its predictive capabilities.

As the training progresses, the curves begin to flatten, demonstrating a phenomenon known as convergence. The blue and orange lines gradually approach a stable loss value around 0.15 to 0.16, suggesting that the model has learned the core characteristics of the dataset and is now making only marginal improvements. This plateauing effect is characteristic of well-performing machine learning models, indicating that the algorithm has effectively captured the underlying data distributions.

The subtle differences between the two curves hint at potential variations in model configuration or training approach. The blue curve shows a more aggressive initial learning rate, while the orange curve exhibits a more gradual descent. These nuanced variations can be attributed to factors such as different initialization strategies, learning rates, or model architectures.

From a practical perspective, the graph suggests optimal training strategies. The rapid initial learning implies that significant model improvements can be achieved relatively quickly. However, the diminishing returns after 40 epochs indicate that continued training beyond this point may provide minimal additional benefits. This insight is crucial for efficient model development, pointing towards potential strategies like early stopping to prevent overfitting and reduce computational overhead.

Ultimately, the visualization provides a window into the learning process, showcasing how neural networks transform from initial, high-error states to refined, more accurate predictive models through the iterative process of training.

However, the model did face some challenges, particularly in predicting ADRs for very rare or novel drug combinations. These drug pairs, which were underrepresented in the training dataset, sometimes resulted in lower prediction accuracy. Additionally, while the model performed well on a variety of drug classes, further refinement is needed to enhance predictions for certain categories of drugs that have highly unpredictable interaction patterns.

Overall, the results suggest that the proposed system provides a robust, scalable, and effective solution for predicting ADRs, offering valuable insights for improving patient safety and drug management.

V. CONCLUSION

In summary, research into the prediction of ADRs and DDIs has evolved significantly over the years, with machine learning and deep learning techniques showing considerable promise. Graph-based models, particularly Graph Neural Networks, have proven effective in representing and predicting drug interactions, while Self-Supervised Learning techniques have the potential to enhance model performance, especially when labeled data is limited. The integration of these approaches could lead to more accurate, scalable, and reliable ADR prediction systems, offering important insights into drug safety and benefiting both patients and healthcare providers.

REFERENCES

[1] Liu, Y., et al. (2017). DeepDDI: A Deep Learning Approach to Predict Drug-Drug Interactions. Bioinformatics, 33(17), 2711-2718.
[2] Wang, Q., et al. (2019). Graph Convolutional Networks for Predicting Adverse Drug Reactions. BMC Bioinformatics, 20(1), 359.
[3] Zhou, X., et al. (2018). A Hybrid Deep Learning Model for Drug-Drug Interaction Prediction. Journal of Pharmacology and Experimental Therapeutics, 365(2), 337-349
[4] Xie, L., et al. (2020). Graph-based Self-Supervised Learning for Drug Safety Prediction. Scientific Reports, 10(1), 14432.
[5] Xie, L., et al. (2021). Reinforcement Learning and Graph Neural Networks for Drug-Drug Interaction Prediction. IEEE Transactions on Biomedical Engineering, 68(7), 2119-212.
[6] Zhang, M., et al. (2020). Drug-Drug Interaction Prediction with Graph Convolutional Networks. Journal of Computational Biology, 27(5), 571-582.
[7] 7Cao, Z., et al. (2018). Drug-Drug Interaction Prediction with Graph Convolutional Networks. Proceedings of the 27th International Conference on Computational Biology, 65-72.
[8] Jin, W., et al. (2020). Self-Supervised Learning for Molecular Property Prediction. Chemical Science, 11(8), 2250-2257.
[9] Khoshgoftaar, T. M., et al. (2007). Predicting Software Defects with Support Vector Machines: A Case Study. Software Quality Journal, 15(3), 215-227.
[10] Xie, L., et al. (2021). Reinforcement Learning and Graph Neural Networks for Drug-Drug Interaction Prediction. IEEE Transactions on Biomedical Engineering, 68(7), 2119-212.



10.22214/IJRASET

45.98

IMPACT FACTOR: 7.129

IMPACT FACTOR: 7.429

INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY